tbuckley/cabot-search huggingface dataset:
Abstract MP16: The Validity of Predictive Equations for 24-Hour Urine Sodium Excretion Among Older Adults and Those with Hypertension: The MESA and CARDIA Urinary Sodium Study
Authors: Norrina B Allen, Lihui Zhao, Catherine Loria, Linda Van Horn, Chia-Yih Wang, Christine Pfieffer, Mary Cogswell, Jacqueline Wright, Kiang Liu
Journal: Circulation (2014)

Background: Excess dietary sodium (Na) intake is linked to adverse cardiovascular health; the population distribution of urinary sodium (UNa) values in the US is unknown. We examined the population distribution of UNa and the validity of existing equations predicting 24-h Na excretion from a single spot urine sample among older adults with and without hypertension. Methods: Demographic, anthropometric, lab, and diet data along with 24-h urine collections were obtained from 555 MESA and CARDIA participants aged 45-79y. One third provided a second 24-h urine collection. Four timed voids (morning, afternoon, evening, and overnight) and the 24-h collection were analyzed for Na, creatinine, potassium and chloride concentrations. We examined the distribution of 24-h excretion of each analyte overall and by gender-race subgroups and hypertensive (HTN) status. We then examined the mean differences (bias) and confidence intervals between measured 24-h UNa excretion and the predicted from spot urine using 4 published equations by specimen timing, race-gender subgroups, and HTN status. Results: Using preliminary data from 265 participants with completed laboratory analysis, 55% female, 61% Black, and 60% had HTN. Mean 24-h Na excretion was 4234 ± 1920 mg for white men, 2706 ± 1136 mg for white women, 3463 ± 1691 mg for Black men and 3415 ± 1635 mg for Black women and did not significantly differ by hypertensive status. Mean bias in predicting 24-h Na excretion overall ranged from -268 (95% CI: -443.5, -91.8) to 1045 (849.3, 1240.4) mg/d. (Table) Conclusion: Among this group of older adults and those with hypertension, the mean 24-h UNa excretion levels for all race-gender groups exceeded current recommendations of 2,300 mg/d, with significant variation by race and gender. All of the four published equations under or overestimated mean 24-h Na excretion when using a single, timed spot urine sample but using evening samples appeared to produce the least bias. These preliminary findings are tentative until confirmed with the full dataset.
The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial
Authors: Giorgio V. Scagliotti, Filippo De Marinis, Massimo Rinaldi, Lucio Crinò, Cesare Gridelli, Sergio Ricci, Yan D. Zhao, Astra M. Liepa, Patrick Peterson, Maurizio Tonato
Journal: Journal of Thoracic Oncology (2009)
<i>Bay Bridge Anchorage Construction</i>
Authors: Thomas B. Cole
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic Nonvalvular Cardiac Disease or Chronic Myocardial Insufficiency and Its Therapeutic Management
Authors: Henry A. Christian
Journal: Annals of Internal Medicine (1931)

Article1 August 1931Chronic Nonvalvular Cardiac Disease or Chronic Myocardial Insufficiency and Its Therapeutic ManagementHENRY A. CHRISTIAN, M.D., F.A.C.P.HENRY A. CHRISTIAN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-5-2-95 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn an adult clinic more patients with cardiac disease without valve lesions are seen than those with valve lesions. Rheumatic fever is the largest cause of valvular disease, and this is chiefly a disease of childhood and early adult life. In children's clinics, apart from congenital heart disease, other than rheumatic valvular disease of the heart is unusual. The majority of patients with rheumatic heart disease die within a twenty year period of the inception of their heart lesion, and they have had the causative rheumatic fever in childhood. The result is a rapidly falling curve of incidence of rheumatic... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Mass.*Read at the Baltimore Meeting of the American College of Physicians, March 23, 1931. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA study of myocardial hypertrophy of uncertain etiology, associated with congestive heart failure 1 August 1931Volume 5, Issue 2Page: 95-99KeywordsCardiovascular therapyChildrenCongenital heart diseaseHeart diseasesLesionsRheumatic feverValvular diseases ePublished: 1 December 2008 Issue Published: 1 August 1931 PDF downloadLoading ...
Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia
Authors: Nozomi Niitsu, Junko Okabe-Kado, Michihiro Nakayama, Naoki Wakimoto, Akiko Sakashita, Nobuo Maseki, Kazuo Motoyoshi, Masanori Umeda, Yoshio Honma
Journal: Blood (2000)
Abstract 1500: The difference of serum RNA profile: RNA detection method
Authors: Satoshi Kondo, Satoko Takizawa, Hideo Akiyama
Journal: Cancer Research (2014)

Abstract Serum miRNA profiles are widely reported by many research groups, but they do not always coincide well. The reason of this difference is suggested to be, at least in some cases, due to a difference in the RNAdetection method. In this report, we compare the miRNA expression data obtained by different detection tools.. In these days, the whole miRNA expression profiling can be done by multiple qRT-PCR, microarrays, and Next Generation Sequencing. However, the feature of each method will reflect to the obtained data and it is no surprise that data obtained by different tools do not match perfectly. We will compare the serum miRNA expression profiles detected by (1) “TaqMan” Array MicroRNA Card (2) QIAGEN miScript miRNA PCR Array (3) “3D-Gene” Human miRNA oligo chip, (4)”HiSeq” Next Generation Sequencer (5) Nanostring “nCounter” Analysis system and discuss the base of method for serum miRNA profiling. Citation Format: Satoshi Kondo, Satoko Takizawa, Hideo Akiyama. The difference of serum RNA profile: RNA detection method. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1500. doi:10.1158/1538-7445.AM2014-1500
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells
Authors: Shigeki Yagyu, Valentina Hoyos, Francesca Del Bufalo, Malcolm K Brenner
Journal: Molecular Therapy (2015)

Human induced pluripotent stem cells (hiPSC) hold promise for regenerative therapies, though there are several safety concerns including the risk of oncogenic transformation or unwanted adverse effects associated with hiPSC or their differentiated progeny. Introduction of the inducible caspase-9 (iC9) suicide gene, which is activated by a specific chemical inducer of dimerization (CID), is one of the most appealing safety strategies for cell therapies and is currently being tested in multicenter clinical trials. Here, we show that the iC9 suicide gene with a human EF1α promoter can be introduced into hiPSC by lentiviral transduction. The transduced hiPSC maintain their pluripotency, including their capacity for unlimited self-renewal and the potential to differentiate into three germ layer tissues. Transduced hiPSC are eliminated within 24 hours of exposure to pharmacological levels of CID in vitro, with induction of apoptosis in 94–99% of the cells. Importantly, the iC9 suicide gene can eradicate tumors derived from hiPSC in vivo. In conclusion, we have developed a direct and efficient hiPSC killing system that provides a necessary safety mechanism for therapies using hiPSC. We believe that our iC9 suicide gene will be of value in clinical applications of hiPSC-based therapy. Human induced pluripotent stem cells (hiPSC) hold promise for regenerative therapies, though there are several safety concerns including the risk of oncogenic transformation or unwanted adverse effects associated with hiPSC or their differentiated progeny. Introduction of the inducible caspase-9 (iC9) suicide gene, which is activated by a specific chemical inducer of dimerization (CID), is one of the most appealing safety strategies for cell therapies and is currently being tested in multicenter clinical trials. Here, we show that the iC9 suicide gene with a human EF1α promoter can be introduced into hiPSC by lentiviral transduction. The transduced hiPSC maintain their pluripotency, including their capacity for unlimited self-renewal and the potential to differentiate into three germ layer tissues. Transduced hiPSC are eliminated within 24 hours of exposure to pharmacological levels of CID in vitro, with induction of apoptosis in 94–99% of the cells. Importantly, the iC9 suicide gene can eradicate tumors derived from hiPSC in vivo. In conclusion, we have developed a direct and efficient hiPSC killing system that provides a necessary safety mechanism for therapies using hiPSC. We believe that our iC9 suicide gene will be of value in clinical applications of hiPSC-based therapy.
Abstract 3942: Serum Metabolomics Identifies Novel Signature Metabolites in Very Early Cardiac Ischaemia: First in Human Study
Authors: Mamas Mamas, Warwick Dunn, Dave Broadhurst, Sanoj Chacko, Marie Brown, Magdi El-Omar, Farzin Fath-Ordoubadi, Bernard Clarke, Roy Goodacre, Doug Kell, Ludwig Neyses
Journal: Circulation (2009)

Early changes in cardiac metabolism during the initial stages of cardiac ischemia are thought to play a major role in pathophysiological processes underlying ischemic preconditioning and sudden car...
Molecular biology of the gene (4th edition) volume II: Specialized aspectsby James D. Watson, Nancy H. Hopkins, Jeffrey W. Roberts, Joan Argetsinger Steitz and Alan M. Weiner. Benjamin/Cummings Publishing Co., 1987. £21.95/$29.95 (xiv + 418 pages) ISBN 0 8053 9613 6
Authors: P GOLDFARB
Journal: Trends in Genetics (1988)
Abstract 1521: Quantitation of HER2 gene amplification using digital PCR
Authors: Kelly Li, Devin Do, Patricia Hegerich, Bruno Ping, David Keys, Nivedita Majumdar, Stephen Jackson, Francisco Cifuentes, Caifu Chen
Journal: Cancer Research (2014)

Abstract Gene amplification is a common genetic abnormality in many types of cancers and has been implicated in playing important roles in cancer development. The most common types of amplified genes are oncogenes and drug-resistance genes. For example, Human epidermal growth factor receptor 2 (HER2) gene amplification, occurring in about 10-30% of breast cancer cases, is strongly associated with aggressive tumor progression and poor prognosis. HER2 also presents an effective therapeutic target, and several HER2 targeting agents have been approved for treatment of HER2 positive breast cancer by FDA. Analysis of HER2 gene amplification is important not only in selecting right patients for HER2 targeting agents but also monitoring the response to therapy and predicting clinical outcomes. Currently, fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) analysis are standard testing approaches for HER2 gene amplification. However, the challenge for these methodologies is that HER2 gene amplification is less quantitative, especially with some samples whose HER2/CEP17 ratio fall into equivocal range, and the workflow is labor intensive. We have developed digital PCR (dPCR) technology on the QuantStudio™ 3D Digital PCR System and quantify gene copy numbers from zero to eight with high accuracy and precision. We analyzed FFPE samples for HER2 gene amplification and our data show that dPCR provides a robust and quantitative detection, simple workflow and a quick turn around time. This study demonstrate that dPCR quantitation of gene amplification could potentially be used to study any loci that are amplified in cancer. Citation Format: Kelly Li, Devin Do, Patricia Hegerich, Bruno Ping, David Keys, Nivedita Majumdar, Stephen Jackson, Francisco Cifuentes, Caifu Chen. Quantitation of HER2 gene amplification using digital PCR. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1521. doi:10.1158/1538-7445.AM2014-1521
Regulation of Dietary Supplements—Reply
Authors: Catherine D. DeAngelis, Phil B. Fontanarosa
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of tumor cells in body cavity fluids by multiparametric flow cytometry and immunocytochemistry.
Authors: Awtar Krishan, Parvin Ganjei-Azar, Merce Jorda, Mehrdad Nadji, Isildinha M. Reis, Ronald M. Hamelik
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

5150 

In the present study, cells from body cavity fluids were examined for nuclear DNA and protein content, nuclear volume and receptor expression by multiparametric flow cytometry (FCM), immunocytochemistry (ICC) utilizing epithelial membrane antigen (EMA), and by conventional cytology. Out of 130 pleural and peritoneal fluids examined, 30 were identified by cytology to contain malignant or “suspicious” cells. 12 of these (40.0%) had DNA index (DI) of >1.2 (henceforth referred to as aneuploid). Eight samples with aneuploid cells were from patients with cirrhosis or end stage liver disease who did not have any malignancy. Analysis of nuclear volume vs. DNA content or protein content vs. DNA content could differentiate between subpopulations with diploid DNA content. Ninety-six samples in which we had data from cytology, ICC and FCM were used for statistical analysis. Data from cytology and ICC had the best agreement with a moderate kappa value (overall agreement relative to expected agreement by chance alone) of 0.585. Agreement was low between cytology and FCM (kappa = 0.200) and between ICC and FCM (kappa = 0.205). ICC had significantly higher sensitivity than cytology (79.4% v. 58.8%, p=0.016) or FCM (79.4% v. 38.2%, p=0.001). Cytology had significantly higher specificity than FCM (96.8% vs. 82.3%, p=0.012). The differences in specificity between IHC and FCM (87.1% v. 82.3%, p=0.607) or ICC and cytology (87.1% v.96.8%, p=0.109) were not statistically significant. Sensitivity increased significantly for the combinations cytology + ICC (79.4%, p=0.016) and cytology + FCM (Se=73.5%, p=0.004) as compared to cytology alone (Se= 58.8%). Also, the combination cytology + FCM had higher sensitivity than FCM alone (73.5% v. 38.2%, p<0.0001). By using high resolution flow cytometric analysis of DNA aneuploidy, nuclear volume and expression of markers such as epithelial membrane antigen (EMA), it may be possible to decrease the 50% false negative rate of conventional cytology for detection of malignant cells in body cavity fluids. In addition we may be able to determine the site of common primary tumors such as breast and lung by using ICC and FCM for estrogen receptor and thyroid transcription factor-1(TTF-I) expression, respectively. Grant support NIH CA09733.
Clinical guidelines may obviate need for
Authors: D Heaney
Journal: BMJ (1996)

EDITOR,—Having read Brian Hurwitz's editorial considering the fate of doctors who deviate from clinical guidelines and how they might fare in court,1 I thought that the everyday reality of clinical guidelines as seen from the perspective of a senior house officer might be of interest. Clinical guidelines are usually issued by specialist departments as an aid to staff. The number of guidelines gradually proliferates: most hospitals …
The Fever Stones
Authors: Phil Bowman
Journal: JAMA (2003)

Risk Factors for Heart Disease Heart disease kills more Americans each year than any other disease or illness.It is important to understand what makes heart disease so common and how you can reduce your chances of having heart disease.Heart disease can be silent (no symptoms) in some persons.They may not be aware of heart disease until they have a heart attack (also known as a myocardial infarction).More than 2600 Americans die every day from cardiovascular (heart and blood vessel) disease.The August 20, 2003, issue of JAMA includes several articles about risk factors for heart disease.A risk factor is something that makes you more likely to have a disease, illness, or medical problem.Some risk factors are modifiable (can be made better).Other risk factors, such as age and genetics (family history), cannot be changed.
Exacerbations and symptoms remain common in patients with asthma control: A survey of 8000 patients in Europe
Authors: David Price, Thys van de Molen, Monica Fletcher
Journal: European Respiratory Journal (2013)

Introduction: Individuals with asthma may experience symptoms, despite achieving guideline-defined control. We report data on symptoms and exacerbations in patients with GINA-defined asthma control and those with perceived control from the largest European survey of asthma.

Methods: Online surveys were conducted with 8000 patients with asthma (aged 18–50 years, ≥2 prescriptions in the past 2 years), recruited via validated consumer panels from 11 countries.

Results: Mean age of respondents was 35 years; 61% were women. GINA-defined levels of controlled, partially controlled and uncontrolled asthma were 20%, 35% and 45%, respectively. No respondent with GINA-defined control reported symptoms or reliever inhaler use on ≥3 days, or night-time awakening on ≥1 day, in the past week; however, 35% of those with controlled asthma and 64% of those with partially controlled asthma reported symptoms on 1 or 2 days in the previous week. Of those with GINA-defined control, 7% had been treated in A&E in the past year, compared with 13% of those with partially controlled and 40% with uncontrolled asthma. Notably, of those with controlled asthma, 24% had ≥1 acute asthma exacerbation (requiring oral steroid use) in the past year. Moreover, 43% of those who perceived their asthma as controlled had an exacerbation. Of those reporting exacerbations (n=3516), 75% did not consider their asthma to be serious.

Conclusions: Asthma control in Europe remains sub optimal. Patients with GINA-defined control continue to have symptoms and exacerbations, highlighting a need for initiatives to improve asthma management. This may also suggest a need to reassess the language used to describe asthma control.
The patient journey: a report of skin cancer care across Europe
Authors: M. Trakatelli, S. Siskou, C. Proby, G.S. Tiplica, B. Hinrichs, E. Altsitsiadis, A. Kitsou, L. Ferrandiz, S. Aquilina, C. Apap, M. Ulrich, C. Fiorentini, C. Magnoni, E. de Vries, S.C. Flohil, K. Kalokasidis, D. Moreno-Ramirez, A. Ruiz-de-Casas, S. Majewski, A. Ranki, S. Pitkänen, O. Saksela, D. Ioannides, D. Sotiriadis, E. Stockfleth
Journal: British Journal of Dermatology (2012)

There are poorly documented variations in the journey a skin cancer patient will follow from diagnosis to treatment in the European Union.To investigate the possible difficulties or obstacles that a person with a skin malignancy in the European Union may have to overcome in order to receive adequate medical screening and care for his/her condition. In addition, we wished to explore differences in European health systems, which may lead to health inequalities and health inequities within Europe.Ten European countries took part in this investigation (in alphabetical order): Finland, Germany, Greece, Italy, Malta, Poland, Romania, Spain, the Netherlands and the U.K. The individual participants undertook local and national enquiries within their own country and completed a questionnaire.This exercise has identified important differences in the management of a skin cancer patient, reflecting major disparities in health care between European countries.Further investigation of health disparities and efforts to address health inequalities should lead to improvements in European health care quality and reduction in morbidity from skin cancer.